Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bommareddy, Praveen K., Rabkin, Samuel D., Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422399/
https://www.ncbi.nlm.nih.gov/pubmed/30906668
http://dx.doi.org/10.1080/2162402X.2019.1571390
_version_ 1783404381870227456
author Bommareddy, Praveen K.
Rabkin, Samuel D.
Kaufman, Howard L.
author_facet Bommareddy, Praveen K.
Rabkin, Samuel D.
Kaufman, Howard L.
author_sort Bommareddy, Praveen K.
collection PubMed
description In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted.
format Online
Article
Text
id pubmed-6422399
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-64223992019-03-22 Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade Bommareddy, Praveen K. Rabkin, Samuel D. Kaufman, Howard L. Oncoimmunology Author's View In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models. MEK inhibition increased viral replication independent of mutation status. Combination therapy increased PD-1/PD-L1 expression and PD-1 blockade further enhanced tumor regression. Further clinical development of this strategy for treating melanomas warranted. Taylor & Francis 2019-02-03 /pmc/articles/PMC6422399/ /pubmed/30906668 http://dx.doi.org/10.1080/2162402X.2019.1571390 Text en © 2019 The Author(s). Published by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's View
Bommareddy, Praveen K.
Rabkin, Samuel D.
Kaufman, Howard L.
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title_full Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title_fullStr Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title_full_unstemmed Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title_short Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
title_sort triple threat to cancer: rationale for combining oncolytic viruses, mek inhibitors, and immune checkpoint blockade
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422399/
https://www.ncbi.nlm.nih.gov/pubmed/30906668
http://dx.doi.org/10.1080/2162402X.2019.1571390
work_keys_str_mv AT bommareddypraveenk triplethreattocancerrationaleforcombiningoncolyticvirusesmekinhibitorsandimmunecheckpointblockade
AT rabkinsamueld triplethreattocancerrationaleforcombiningoncolyticvirusesmekinhibitorsandimmunecheckpointblockade
AT kaufmanhowardl triplethreattocancerrationaleforcombiningoncolyticvirusesmekinhibitorsandimmunecheckpointblockade

Ejemplares similares